PortfoliosLab logoPortfoliosLab logo
ISIN
US92189F6925
CUSIP
92189F692
Issuer
VanEck
Inception Date
Dec 20, 2011
Region
Global (Broad)
Leveraged
1x (No leverage)
Index Tracked
MVIS US Listed Pharmaceutical 25 Index
Distribution Policy
Distributing
Asset Class
Equity
Asset Class Size
Multi-Cap
Asset Class Style
Blend
Assets Under Management
$866M

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

PPH Performance Chart

VanEck Pharmaceutical ETF (PPH) is up 1.1% since the beginning of the year. PPH is currently trading at $103 per share. Investors who bought $1,000 worth of PPH shares 5 years ago would now be looking at an investment worth $1,573.


Loading charts...

S&P 500 Index

Returns By Period

VanEck Pharmaceutical ETF (PPH) has returned 1.11% so far this year and 21.33% over the past 12 months. Over the last ten years, PPH has returned 8.33% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.


VanEck Pharmaceutical ETF

1D
0.92%
1M
-1.45%
YTD
1.11%
6M
1.61%
1Y
21.33%
3Y*
11.87%
5Y*
9.48%
10Y*
8.33%

Benchmark (S&P 500 Index)

1D
-0.37%
1M
-0.01%
YTD
9.16%
6M
8.64%
1Y
25.22%
3Y*
19.78%
5Y*
11.99%
10Y*
13.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PPH Monthly Returns History

Based on dividend-adjusted daily data since Feb 1, 2000, PPH's average daily return is +0.03%, while the average monthly return is +0.54%. At this rate, an investment would double in approximately 10.7 years.

Historically, 60% of months were positive and 40% were negative. The best month was Apr 2020 with a return of +12.0%, while the worst month was Feb 2009 at -12.4%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.

On a daily basis, PPH closed higher 51% of trading days. The best single day was Oct 13, 2008 with a return of +10.2%, while the worst single day was Mar 16, 2020 at -9.0%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20263.53%4.58%-7.00%-1.15%2.84%-1.21%1.11%
20253.06%5.32%-2.69%-1.26%-1.64%-0.03%-5.06%7.17%1.67%2.86%10.77%0.94%22.00%
20244.83%4.10%2.14%-2.89%3.31%1.13%2.15%6.82%-4.43%-3.50%-1.28%-3.83%8.05%
20230.77%-3.43%2.62%2.47%-4.08%4.12%2.60%1.84%-2.49%-5.29%4.25%4.03%6.95%
2022-1.44%-0.18%5.35%-2.23%2.17%-3.02%0.40%-8.01%-4.95%8.78%5.74%1.23%2.64%
20212.51%-0.90%2.21%1.24%3.78%1.26%2.87%1.58%-4.23%3.69%-4.95%8.12%17.79%

Benchmark Metrics

VanEck Pharmaceutical ETF has an annualized alpha of 1.72%, beta of 0.65, and R2 of 0.47 versus S&P 500 Index. Calculated based on daily prices since February 01, 2000.

  • This ETF participated in 70.44% of S&P 500 Index downside but only 66.36% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.65 may look defensive, but with R2 of 0.47 this ETF is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this ETF's risk.
  • R2 of 0.47 means the benchmark explains less than half of this ETF's behavior - treat beta with caution or consider switching to a more representative benchmark.

Alpha
1.72%
Beta
0.65
0.47
Upside Capture
66.36%
Downside Capture
70.44%

Expense Ratio

PPH has an expense ratio of 0.36%, placing it in the medium range.


Return for Risk

Risk / Return Rank

PPH ranks 36 for risk / return — below 36% of ETFs on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.


PPH Risk / Return Rank: 3636
Overall Rank
PPH Sharpe Ratio Rank: 3535
Sharpe Ratio Rank
PPH Sortino Ratio Rank: 3838
Sortino Ratio Rank
PPH Omega Ratio Rank: 3434
Omega Ratio Rank
PPH Calmar Ratio Rank: 4141
Calmar Ratio Rank
PPH Martin Ratio Rank: 3434
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for VanEck Pharmaceutical ETF (PPH) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PPHBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-0.81

Sortino ratioReturn per unit of downside risk

-0.84

Omega ratioGain probability vs. loss probability

1.22

1.37

-0.15

Calmar ratioReturn relative to maximum drawdown

1.99

2.78

-0.79

Martin ratioReturn relative to average drawdown

4.86

12.44

-7.58

Dividends

Dividend History

VanEck Pharmaceutical ETF provided a 2.08% dividend yield over the last twelve months, with an annual payout of $2.15 per share. The fund has been increasing its distributions for 3 consecutive years.


1.60%1.80%2.00%2.20%2.40%$0.00$0.50$1.00$1.50$2.0020152016201720182019202020212022202320242025
Dividends
Dividend Yield
PeriodTTM20252024202320222021202020192018201720162015
Dividend$2.15$1.84$1.71$1.70$1.20$1.25$1.11$1.14$1.08$1.14$1.27$1.26

Dividend yield

2.08%1.78%1.98%2.09%1.55%1.62%1.66%1.77%1.97%1.92%2.43%1.93%

Monthly Dividends

The table displays the monthly dividend distributions for VanEck Pharmaceutical ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.00$0.00$0.00$0.84$0.00$0.00$0.84
2025$0.00$0.00$0.00$0.52$0.00$0.00$0.61$0.00$0.00$0.39$0.00$0.31$1.84
2024$0.00$0.00$0.00$0.53$0.00$0.00$0.36$0.00$0.00$0.41$0.00$0.41$1.71
2023$0.00$0.00$0.00$0.66$0.00$0.00$0.39$0.00$0.00$0.34$0.00$0.31$1.70
2022$0.00$0.00$0.00$0.44$0.00$0.00$0.25$0.00$0.00$0.27$0.00$0.24$1.20
2021$0.00$0.00$0.00$0.35$0.00$0.00$0.29$0.00$0.00$0.35$0.00$0.27$1.25

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the VanEck Pharmaceutical ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the VanEck Pharmaceutical ETF was 51.45%, occurring on Mar 3, 2009. Recovery took 917 trading sessions.

The current VanEck Pharmaceutical ETF drawdown is 6.61%.


Related event

Drawdown

Fall

Recovery

Underwater

Financial crisis2007–2009
-51.45%Mar 2009
8y 2mo3y 7mo
11y 9moDec 2000 - Oct 2012
COVID crash2020
-30.19%Mar 2020
4y 7mo9mo 19d
5y 5moAug 2015 - Jan 2021
Dot-com crash2000–2002
-21.59%Mar 2000
27d28d
1mo 25dFeb 2000 - Apr 2000
Bear market2022
-20.26%Sep 2022
5mo 19d10mo 15d
1y 3moApr 2022 - Aug 2023
2025 selloff2025
-18.06%Apr 2025
7mo 9d7mo 5d
1y 2moSep 2024 - Nov 2025

Drawdown Indicators


PPHBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-51.45%

-56.78%

+5.33%

Max Drawdown (1Y)

Largest decline over 1 year

-10.76%

-9.10%

-1.66%

Max Drawdown (3Y)

Largest decline over 3 years

-18.06%

-18.90%

+0.84%

Max Drawdown (5Y)

Largest decline over 5 years

-20.26%

-25.43%

+5.17%

Max Drawdown (10Y)

Largest decline over 10 years

-29.70%

-33.92%

+4.22%

Current Drawdown

Current decline from peak

-6.61%

-1.80%

-4.81%

Average Drawdown

Average peak-to-trough decline

-17.29%

-10.71%

-6.58%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.40%

2.03%

+2.37%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Portfolio Analyzer

Build a portfolio with PPH

Add VanEck Pharmaceutical ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with PPH